This publication is intended as an educational resource for New Zealand health professionals who manage patients with heart failure. The focus of this publication is on hyperkalaemia in patients with heart failure with reduced ejection fraction (HFrEF), with a focus on the role of the sodium-glucose co-transporter 2 (SGLT2) inhibitors.
Please login below to download this issue (PDF)